3 Surefire Stocks to Buy on the Dip and Hold for a Decade

The article argues that HCA Healthcare, MercadoLibre, and Visa are attractive buy-the-dip candidates despite near-term headwinds. HCA faces inflation and recession risk, MercadoLibre is spending heavily to expand financial services and e-commerce ecosystem growth, and Visa is contending with antitrust and legislative pressure. Overall tone is constructive on long-term fundamentals, but the piece is opinion-driven and unlikely to have a large immediate market impact.

Analysis

This setup is less about “cheap quality” and more about three distinct rewiring stories where near-term P&L pressure is obscuring longer-duration optionality. The common thread is that each company is spending into a moat defense or moat expansion phase, which usually looks inefficient until the operating leverage reasserts itself; that makes the next 2-6 quarters the key window for sentiment to stabilize. The market is currently treating all three as if execution risk is permanent, which creates room for multiple expansion if even one or two operating metrics inflect.

The most interesting second-order dynamic is competitive asymmetry. In healthcare, scale and capital intensity tend to punish marginal entrants first, so any macro slowdown can actually reinforce HCA’s relative position versus smaller operators that cannot absorb wage or reimbursement volatility as easily. In Latin American commerce and fintech, MELI’s spend is effectively subsidizing ecosystem lock-in; that hurts near-term margins but increases switching costs for merchants and consumers, especially if payments and credit adoption keep compounding. For Visa, the legal overhang may matter more for multiple compression than for cash-flow damage; the risk is not outright business disruption but a long period of headline uncertainty that caps the stock unless regulators force a real change in interchange economics.

Consensus is likely underestimating duration. The easy bearish read is that HCA is cyclical, MELI is over-investing, and Visa is “mature,” but that misses how each business can turn a temporary drag into a stronger competitive moat if the environment normalizes before capital intensity becomes structurally higher. The bigger risk is not any single headline; it is if macro softness plus regulatory pressure persist long enough to force all three into slower reinvestment, which would delay the re-rating by multiple quarters.

Key Decisions for Investors

• Initiate a 6-12 month long V position on weakness; thesis is regulatory overhang caps the multiple more than earnings power, with a favorable asymmetry if courts or legislation fail to force structural change.
• Add HCA on macro-driven selloffs and hold 12-24 months; this is a relative-quality long versus smaller healthcare operators that are more exposed to labor and financing stress.
• For MELI, use a staggered entry over 3-6 months rather than a lump sum; treat it as an ecosystem-compounding trade where margin compression is the near-term cost of a higher terminal value, but size smaller due to execution risk.
• Pair trade: long V / short a basket of highly regulated payment-adjacent names with weaker moat durability; this isolates the moat-vs-headline distinction and reduces market beta.
• Avoid chasing after relief rallies; wait for implied volatility to cool or for a second selloff, then express the view with either equity or 6-12 month calls to cap downside while keeping upside convexity.